News headlines about Stryker (NYSE:SYK) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Stryker earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the medical technology company an impact score of 45.8005270502733 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s analysis:
- Pre-Market Technical Scan on Medical Equipment Equities — Smith & Nephew, Zimmer Biomet, Abbott Labs, and Stryker – PR Newswire (press release) (prnewswire.com)
- Stryker Corporation (SYK) – Momentum Stock in Focus – Wall Street Morning (wallstreetmorning.com)
- Stryker Corporation (SYK) Ex-Dividend Date Scheduled for December 28, 2017 – Nasdaq (nasdaq.com)
- Jazz Pharmaceuticals PLC (JAZZ) Director Sells 9000 Shares of Stock (nismagazine.com)
- Tradition Capital Management Decreased Stryker (SYK) Holding; Teachers Insurance & Annuity Association Of … – Hill Country Times (hillcountrytimes.com)
Shares of Stryker (NYSE SYK) opened at $154.84 on Friday. The company has a market cap of $57,947.01, a PE ratio of 24.54, a PEG ratio of 2.44 and a beta of 0.78. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. Stryker has a 1-year low of $116.50 and a 1-year high of $160.62.
Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.97 billion. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The firm’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.39 earnings per share. sell-side analysts expect that Stryker will post 6.47 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 31st. Stockholders of record on Friday, December 29th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.88 annualized dividend and a dividend yield of 1.21%. This is an increase from Stryker’s previous quarterly dividend of $0.43. Stryker’s dividend payout ratio is currently 40.17%.
SYK has been the topic of several research analyst reports. Wells Fargo & Co increased their target price on shares of Stryker from $160.00 to $166.00 in a research note on Friday, October 27th. Canaccord Genuity raised their price objective on shares of Stryker from $155.00 to $162.00 and gave the company a “buy” rating in a research note on Friday, October 27th. Stifel Nicolaus raised their price objective on shares of Stryker from $158.00 to $168.00 and gave the company a “buy” rating in a research note on Friday, October 27th. Cowen set a $160.00 price objective on shares of Stryker and gave the company a “buy” rating in a research note on Friday, October 6th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and issued a $155.00 price objective on shares of Stryker in a research note on Monday, October 2nd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $154.20.
In related news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the sale, the insider now owns 83,207 shares in the company, valued at $12,925,375.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Stryker (SYK) Earning Somewhat Positive News Coverage, Report Finds” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2017/12/31/stryker-syk-earning-somewhat-positive-news-coverage-study-finds-updated-updated.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Stryker and related companies with MarketBeat.com’s FREE daily email newsletter.